3rd Quarter - Report

COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

Firm
Client
Income
$130,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to biopharmaceutical innovation and intellectual property (no bill); issues related to intellectual property and Bayh-Dole in the Genomic Data Protection Act (S. 863 / no House bill); induced infringement.

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —
JENNIFER L PLITSCH —
MICHAEL STERN —

Bills named: S. 863 (119th)

Health Issues HCR

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —
RICHARD F KINGHAM —
JENNIFER L PLITSCH —
MICHAEL STERN —

Contacted: SENATE

Bills named: S. 1414 (119th), S. 355 (119th), S. 1097 (119th), H.R. 5526 (119th), S. 2658 (119th), S. 2620 (119th), S. 1954 (119th), S. 2256 (119th), S. 2296 (119th), H.R. 2821 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.